The role of the thymus in HIV-1 pathogenesis remains unclear. We developed an assay to
quantify the number of recent thymic emigrants in blood based on the detection of a major …

Immune activation is a major characteristic of human immunodeficiency virus type 1 (HIV-1)
infection and a strong prognostic factor for HIV-1 disease progression. The underlying …

Background Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …

Carrier-mediated transport across cell membranes is an important determinant of activity,
resistance, and toxicity of chemotherapeutic agents including antiretroviral (ARV) drugs (ARDs)…

Background Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil
fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed …

Background Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has
shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults …

Hodgkin's disease (HD) is the most common non‐acquired immunodeficiency syndrome (AIDS)‐defining
malignancy in human immunodeficiency virus (HIV)‐infected patients. We …

To date, most studies have focused on the characterization of HIV-1–specific cellular immune
responses in the peripheral blood (PB) of infected individuals. Much less is known about …

Background In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed
non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and …

Objective “Choosing Wisely” is a growing international campaign aiming at practice
changes to improve patient health and safety by both, conduct of essential and avoidance of …